Migraine Trial, Recruiting NCT05700318 Sponsor: ShiraTronics Condition: Migraine
Back to Migraine

Migraine Trial, Recruiting

NCT05700318
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 22 years of age or older.
  • People who have had a history of migraines for at least 12 months.
  • People who experience between 15 and 26 headache days per month, with at least 8 of those days involving migraine-type headaches.
  • People who have not responded well to, are unable to take, or are not suited to two specific migraine treatments — Botox (onabotulinumtoxin A) and a class of medications called CGRP monoclonal antibodies.
  • People who have been on a stable migraine medication routine.

Who may not be able to join:

  • People whose headaches are caused by a head injury (post-traumatic headache).
  • People whose headaches are caused or worsened by overusing pain or headache medications.
  • People who have a condition called "new daily persistent headache," where constant headaches began suddenly.
  • People who experience headaches that never go away and never provide any relief at all.
  • People who already have a nerve stimulation device implanted to treat headaches.
  • People who have previously had a procedure called cervical radiofrequency ablation, or any other procedure or device used to treat migraines.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Scientific Advisory Board, ShiraTronics

Phone: 1-844-228-7330

Australian sites

Genesis Research Services, Broadmeadow, New South Wales
+61 2 4985 1860
Australian Medical Research, Hurstville, New South Wales
+61 (02) 9570 5550
CerCare, Wayville, South Australia
+61 410 567 855
Paincare Perth, Perth, Western Australia
+61 8 9284 6005

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
ShiraTronics
Registry
ClinicalTrials.gov
Start date
5 May 2023
Est. completion
1 March 2025

Where this trial is recruiting

🇦🇺 Australia

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Monthly Headache Days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov